Family History and Cancer Risk Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

1868 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators from Vanderbilt University Medical Center (VUMC), Duke University, and Meharry Medical College (MMC) are collaborating on a family health history study to deploy a family health history (FHH) platform, MeTree. Recruited participants will complete surveys, the MeTree questionnaire, and MeTree will determine the participant's cancer risk based on current guidelines. The study team will offer genetic counseling to high-risk participants. Investigators will track participant outcomes and behaviors from the use of MeTree to determine the efficiency of the use of MeTree compared to completion of pedigrees in clinic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)

NCT00341757

Cancer

COMPLETED

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

NCT04015102

Prostate Cancer

COMPLETED

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer

NCT00001163

Hereditary Neoplasms Cancer Genetic Predisposition to Cancer +1 more

ACTIVE_NOT_RECRUITING

Family History Study on Cancer Risk

NCT04145388

Lynch Syndrome Colorectal Cancer Breast Cancer +3 more

ACTIVE_NOT_RECRUITING NA

Inherited CAncer REgistry

NCT03231891

Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

From the earliest recognition of cancer-prone families over 100 years ago, clinicians have depended on the family health history (FHH) to identify and treat patients and family members who may have a cancer family syndrome. Once identified, patients can be offered lifesaving, evidence-based management strategies for many of these conditions. To fully realize the benefits of genetic healthcare, however, at risk individuals must be recognized, offered genetic counseling and testing, and then referred for specialized therapy or enhanced screening. While this is a promising time for these patients and families, there are significant challenges to implement a modern and efficient care delivery model across the many patients, provider, and health system stakeholders.

The practice of genetic medicine is changing as genetic discoveries are translated into new tests for an increasing number of health indications. In fact, the prevalence of high-risk individuals who are at risk for hereditary cancer has been rising due to new testing strategies. This has placed enormous pressure on the hospitals and clinics providing care for high-risk patients. Coupled with the healthcare systems need for greater efficiency, the traditional genetic clinic-based practice has become untenable. Barriers and challenges include low numbers of trained genetic workforce, lack of integrated FHH tools for patients and physicians, and long wait times for available clinic appointments. Further, while cancer syndromes are seen across all groups, gaps in care exist as underserved populations are often not recognized and referred for care.

Investigators propose that these barriers can be overcome by using innovations in informatics and telecommunications to develop a sustainable and scalable genomic care delivery model that can be replicated by other health systems. Such a program would need to integrate FHH applications that collect and analyze family data, SMART-on-FHIR capabilities that can link third party apps with the electronic medical record (EMR), and clinical decision support modules to assist providers and patients. MeTree is one such system with all these capabilities -- a validated and flexible patient-facing FHH collection tool that supports SMART-on-FHIR technology. This platform was the backbone of the Implementing Genomics in Practice (IGNITE) network's FHH clinical utility study that showed clear improvements in the quality and quantity of FHH collected in 5 geographically diverse primary care practices. Furthermore, MeTree was highly acceptable to patients and providers, and was able to properly identify participants at risk for 23 hereditary cancer syndromes for genetic counseling referral.

Our re-submission for this Beau Biden Moonshot grant opportunity is based on the hypothesis that an implementation science approach will improve the identification and management of high-risk patients from diverse clinical setting by systematically integrating FHH driven evidence-based guidelines into the EMR. Investigators plan to improve ascertainment of high-risk patients by imbedding MeTree in the workflow of primary and cancer care clinics. This will improve identification for genetic counseling, facilitate patient education about genetic testing, and risk management for at risk patients, as well as facilitate engagement of patients, family members, and providers with telegenetic and telephone counseling options. This collaborative effort from genetic, genomic, biomedical informatic, and implementation science researchers at Vanderbilt University Medical Center (VUMC), Meharry Medical Center (MMC) and Duke University is highly responsive to the five required elements in RFA-CA-19-017. The proposal has the following specific aims:

SA1. Deploy a care delivery model that will facilitate systematic risk assessment for hereditary cancers in diverse clinical environments.

* 4000 participants will be enrolled and randomized to usual care or MeTree FHH risk assessment
* Deploy in academic medical center (VUMC) and a medical center (MMC) that serves underserved populations
* Assess participants perceptions using online survey and qualitative semi-structured interviews

SA2. Improve access to genetic healthcare providers for participants at risk for hereditary cancer syndromes.

* 300 high risk participants in the VUMC Hereditary Cancer Clinic will be enrolled and randomized
* Extend clinic capacity by lessening the need for in-clinic family history collection and basic counseling
* Expand reach of clinic by using telephone and video genetic counseling, referral to specialists

SA3. Explore the feasibility of our care delivery model to improve family engagement for cancer risk assessment

* Participants extend invitations to MeTree's family resource center to share results of genetic tests
* Assist with education and referral needed for cascade testing for pathogenic variants

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer-related Problem/Condition Family Characteristics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Participants with MeTree recommendations and clinic visits with Genetic Counselors are compared to visits without MeTree recommendations to determine if MeTree improves quality and time of visit.

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Risk / MeTree

High risk for hereditary cancer and completes the MeTree questionnaire

Group Type OTHER

MeTree Questionnaire

Intervention Type BEHAVIORAL

MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.

MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MeTree Questionnaire

MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.

MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receiving care at sites included in study
* Able to read and communicate in English
* Willing to use the Internet
* Currently enrolled in the patient portal, or willing to enroll (VUMC-specific)

Exclusion Criteria

* Non-study site patient
* Diagnosed with a terminal illness
* Unable to speak/read English
* Unable/unwilling to use the Internet
* Previous genetic testing and/or counseling from the VUMC Hereditary Cancer Clinic

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes